옵션 체인은 다양한 행사가격과 만기일에 대한 Surgery Partners의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Surgery Partners에 대한 시장 심리를 평가합니다..

Surgery Partners (NASDAQ:SGRY) 주식, 옵션 체인

Surgery Partners

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.

Equities

Mid Cap

News

Movers

Trading Ideas

AKRO

Brighthouse Financial, Inc. - Common Stock

Hims & Hers Health, Inc. Class A Common Stock

HIMS

SGRY

VIAV

이 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아케로 테라퓨틱스(NASDAQ:AKRO)의 주가는 회사가 에프룩시퍼민(Efruxifermin)에 대한 SYMMETRY 2B상 연구의 96주차 예비 결과를 보고한 후 주가는 106.57% 급등했다. 몇몇 애널리스트들이 목표 주가를 상향 조정했다.

아케로 테라퓨틱스, 브링커 인터내셔널, 비아비 등 지난주 최대 상승한 중형주 (1월 27일-1월 31일)

Surgery Partners Inc

WIIM

RGTI

Rigetti Computing shares are trading higher, reversing after falling Wednesday on a Q4 revenue miss.

Citigroup analyst Daniel Grosslight reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Sell and maintains $27 price target.

Price Target

Reiteration

Analyst Ratings

Citigroup Reiterates Sell on Hims & Hers Health, Maintains $27 Price Target

Financial giants have made a conspicuous bearish move on Astera Labs. Our analysis of options history for Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) revealed 10 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 60% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $192,986, and 4 were calls, valued at $164,488.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $120.0 for Astera Labs over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Astera Labs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale trades within a strike price range from $20.0 to $120.0 in the last 30 days. 
<h3>Astera Labs 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741277781_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.3</td>
<td>$1.05</td>
<td>$1.15</td>
<td>$90.00</td>
<td>$69.0K</td>
<td>2.6K</td>
<td align="right">34</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$53.5</td>
<td>$53.1</td>
<td>$53.1</td>
<td>$115.00</td>
<td>$53.1K</td>
<td>107</td>
<td align="right">10</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.5</td>
<td>$4.2</td>
<td>$4.32</td>
<td>$65.00</td>
<td>$43.2K</td>
<td>20</td>
<td align="right">150</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.9</td>
<td>$9.8</td>
<td>$9.8</td>
<td>$55.00</td>
<td>$31.3K</td>
<td>14</td>
<td align="right">62</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.9</td>
<td>$9.8</td>
<td>$9.8</td>
<td>$55.00</td>
<td>$29.4K</td>
<td>14</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Astera Labs</h3>
Astera Labs Inc designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates semiconductor technology, microcontrollers, sensors, and software to enhance performance, scalability, and data management. The company offers products such as integrated circuits (ICs), boards, and modules, catering to hyperscalers and system OEMs. The company's solutions focus on data, network, and memory management in AI-driven platforms.
Following our analysis of the options activities associated with Astera Labs, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Astera Labs</h3>
<ul>
<li>Trading volume stands at 1,918,093, with ALAB's price down by -5.02%, positioned at $65.12.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 79 days.</li>
</ul>
<h3>Professional Analyst Ratings for Astera Labs</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $132.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $140. 
&#x2A; Consistent in their evaluation, an analyst from Craig-Hallum keeps a Buy rating on Astera Labs with a target price of $125. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Astera Labs options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

ALAB

This Is What Whales Are Betting On Astera Labs

Whales with a lot of money to spend have taken a noticeably bearish stance on Zscaler.
Looking at options history for Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 69% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $72,242 and 11, calls, for a total amount of $501,065.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $240.0 for Zscaler, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Zscaler's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Zscaler's substantial trades, within a strike price spectrum from $120.0 to $240.0 over the preceding 30 days.
<h3>Zscaler Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741277776_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.2</td>
<td>$24.45</td>
<td>$24.75</td>
<td>$240.00</td>
<td>$96.5K</td>
<td align="right">608</td>
<td align="right">35</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$12.0</td>
<td>$11.7</td>
<td>$12.0</td>
<td>$210.00</td>
<td>$66.0K</td>
<td align="right">587</td>
<td align="right">187</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$20.65</td>
<td>$20.1</td>
<td>$20.2</td>
<td>$230.00</td>
<td>$60.6K</td>
<td align="right">271</td>
<td align="right">38</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$5.25</td>
<td>$4.8</td>
<td>$5.25</td>
<td>$207.50</td>
<td>$47.2K</td>
<td align="right">218</td>
<td align="right">377</td>
</tr>
<tr>
<td>ZS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.44</td>
<td>$2.43</td>
<td>$2.43</td>
<td>$240.00</td>
<td>$46.1K</td>
<td align="right">761</td>
<td align="right">788</td>
</tr>
</tbody>
</table>

<h3>About Zscaler</h3>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
Having examined the options trading patterns of Zscaler, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Zscaler</h3>
<ul>
<li>Currently trading with a volume of 2,742,553, the ZS's price is up by 6.93%, now at $210.07. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 84 days.</li>
</ul>
<h3>What The Experts Say On Zscaler</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $236.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Zscaler with a target price of $233. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Zscaler with a target price of $250. 
&#x2A; An analyst from Wedbush has decided to maintain their Outperform rating on Zscaler, which currently sits at a price target of $240. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Zscaler, targeting a price of $210. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Zscaler, targeting a price of $250. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Zscaler with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Zscaler's Latest Options Trends

Financial giants have made a conspicuous bearish move on Spotify Technology. Our analysis of options history for Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) revealed 13 unusual trades.
Delving into the details, we found 23% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $227,134, and 9 were calls, valued at $1,491,231.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $210.0 and $575.0 for Spotify Technology, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Spotify Technology options trades today is 242.91 with a total volume of 449.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Spotify Technology's big money trades within a strike price range of $210.0 to $575.0 over the last 30 days.
<h3>Spotify Technology Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741277770_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$181.85</td>
<td>$179.1</td>
<td>$179.1</td>
<td>$430.00</td>
<td>$591.0K</td>
<td align="right">82</td>
<td align="right">33</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$141.7</td>
<td>$139.3</td>
<td>$141.7</td>
<td>$460.00</td>
<td>$396.2K</td>
<td align="right">32</td>
<td align="right">28</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$12.4</td>
<td>$9.6</td>
<td>$9.6</td>
<td>$572.50</td>
<td>$144.0K</td>
<td align="right">18</td>
<td align="right">160</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$10.0</td>
<td>$9.3</td>
<td>$9.3</td>
<td>$572.50</td>
<td>$139.5K</td>
<td align="right">18</td>
<td align="right">8</td>
</tr>
<tr>
<td>SPOT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$20.4</td>
<td>$19.4</td>
<td>$20.1</td>
<td>$470.00</td>
<td>$100.5K</td>
<td align="right">80</td>
<td align="right">51</td>
</tr>
</tbody>
</table>

<h3>About Spotify Technology</h3>
Spotify is the leading global music streaming service provider, with nearly 700 million monthly active users and over 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.
Having examined the options trading patterns of Spotify Technology, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Spotify Technology's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 543,518, the SPOT's price is down by -2.28%, now at $573.47. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 47 days.</li>
</ul>
<h3>Professional Analyst Ratings for Spotify Technology</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $700.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Spotify Technology, which currently sits at a price target of $675. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Spotify Technology, maintaining a target price of $720. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Spotify Technology with a target price of $675. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on Spotify Technology, maintaining a target price of $700. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Spotify Technology, maintaining a target price of $730. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Spotify Technology, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

SPOT

Looking At Spotify Technology's Recent Unusual Options Activity

JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Overweight and lowers the price target from $22 to $15.

ITOS

JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $15

Russian Deputy Finance Minister Vladimir Kolychev's statement on Wednesday that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) will not be included in the National Wealth Fund mirrors President Vladimir Putin's <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667932/did-vladimir-putin-just-ban-bitcoin-mining-in-russia-the-devil-is-in-the-details">historically cautious approach to cryptocurrency</a>.
What Happened: Kolychev, <a href="https://www.interfax.ru/business/1011938">speaking</a> to Interfax on Wednesday, confirmed that the country&#8217;s national wealth fund will maintain its focus on gold and yuan, with allocations of up to 60% in yuan and 40% in gold, explicitly rejecting Bitcoin due to its volatility.
"From a sovereign budget reserve perspective, it is crucial that the fund's assets are highly liquid and can be quickly sold without significant loss in value," he said, adding, "Digital assets are highly volatile, so we have never considered them for the NWF and have no plans to do so in the future." 
The NWF, valued at 11.97 trillion rubles ($122.09 billion) as of February 1, 2025—or 5.6% of projected 2025 GDP—falls below the 7-10% GDP threshold Kolychev cited for considering riskier assets, reinforcing the decision to exclude Bitcoin.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44151349/coinbase-rekindles-efforts-to-introduce-tokenized-securities-in-the-us">Coinbase Rekindles Efforts To Introduce Tokenized Securities In The US</a>
Why It Matters: Putin's comments over the years provide a backdrop to this policy.
In 2021, he acknowledged Bitcoin's potential but flagged its instability, stating, "Bitcoin has value, but it's too unstable for oil trade," <a href="https://www.cnbc.com/2021/10/14/russias-putin-says-crypto-has-value-but-maybe-not-for-trading-oil.html">according</a> to a report.
This followed his 2017 push for regulation to curb risks like money laundering, a stance that evolved into a structured framework by 2024. 
But his administration also banned crypto payments in 2022, reflecting a pattern of embracing crypto's utility—such as in international trade to counter sanctions—while restricting its role in domestic finance.
Putin's earlier engagement with blockchain, such as his 2017 meeting with Ethereum founder Vitalik Buterin at the St. Petersburg International Economic Forum, signaled openness to the technology's potential, but always within a controlled framework. 
In December 2024, <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42317460/vladimir-putin-says-nobody-can-ban-bitcoin-stresses-crypto-will-develop-one-way-or-the-other">Putin famously said</a> that &#8220;nobody can ban Bitcoin,&#8221; emphasizing the power of decentralized technology.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44148430/bitscrunch-acquires-nidum-ai-to-build-decentralized-ai-compute-network">BitsCrunch Acquires Nidum AI To Build Decentralized AI Compute Network</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Media

$BTC

Vladimir Putin Said 'Nobody Can Ban Bitcoin,' But Russia Isn't Looking To Follow Donald Trump's Push For A Crypto Reserve

Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) has outperformed the market over the past 5 years by 6.91% on an annualized basis producing an average annual return of 21.86%. Currently, Allison Transmission has a market capitalization of $8.30 billion. 
Buying $1000 In ALSN: If an investor had bought $1000 of ALSN stock 5 years ago, it would be worth $2,774.32 today based on a price of $95.86 for ALSN at the time of writing.
<h3>Allison Transmission's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741277709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

Here's How Much $1000 Invested In Allison Transmission 5 Years Ago Would Be Worth Today

GRRR

Gorilla Technology Group shares are trading lower following a report from The Bear Cave.

JP Morgan analyst Rachel Vatnsdal maintains Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) with a Neutral and lowers the price target from $20 to $19.

NVST

JP Morgan Maintains Neutral on Envista Holdings, Lowers Price Target to $19

Home improvement retailer Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has introduced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44163340/the-home-depot-introduces-magic-apron-a-suite-of-advanced-ai-tools-to-help-customers-with-their-ho" rel="noreferrer noopener">new tool named Magic Apron</a> which utilizes generative AI to support customers with various home improvement tasks.
Created to address both how-to and product-related queries, Magic Apron provides expert help in time for the busy spring shopping period. Available 24/7, it assists customers with their project and product questions at any time.
Magic Apron is a unique set of tools driven by advanced language models. These models are trained on The Home Depot&#8217;s product database and project expertise, as well as a wide array of online sources, to enhance search results and provide better customer support.
With its debut, Magic Apron stands as the first AI-powered tool specifically designed for the home improvement industry, according to Home Depot.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44161744/why-nauticus-robotics-stocks-are-soaring-today" rel="noreferrer noopener">Why Is Nauticus Robotics Stock Soaring Today?</a>
&#8220;Home Depot customers have always relied on the expertise of our orange-aproned associates in the aisles of our stores to answer questions and help them solve problems,&#8221; said Jordan Broggi, executive vice president of customer experience and president &#8211; online.
&#8220;Magic Apron is designed to bring that same expertise to the digital world, leveraging our proprietary knowledge base to support our customers and give them the confidence to tackle their home improvement projects, anytime, anywhere.&#8221;
For instance, customers getting their lawns ready for spring can ask Magic Apron questions about aerating, overseeding, fertilizing, and controlling weeds.
The tool provides step-by-step instructions, product recommendations, and expert advice. Currently, Magic Apron is available on millions of product pages on homedepot.com and through The Home Depot&#8217;s mobile app, offering customers easy access to helpful project guides and product reviews.
Magic Apron will soon be available on The Home Depot&#8217;s Pro B2B site, providing tailored support for professional contractors and business account users.
Price Action: HD shares are trading higher by 0.17% at $387.00 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44149088/disney-cuts-200-jobs-across-abc-and-tv-networks-amid-restructuring" target="_blank" rel="noreferrer noopener">Disney Cuts 200 Jobs Across ABC News And Disney Entertainment Networks: Report</a></li>
</ul>
Photo: Sockagphoto via Shutterstock.

General

Meet Magic Apron: Home Depot Launches Generative AI Tool To Enhance Spring Shopping

Macro Economic Events

Economics

SPDR Dow Jones Industrial Average ETF Trust

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Major indexes are lower as investors assess US tariff policy. Additionally, Marvell dropped following roughly in-line guidance, which could be weighing on some chip stocks.

Shares of MongoDB Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) tanked in early trading on Thursday, despite the company reporting <a href="https://www.benzinga.com/news/earnings/25/03/44153596/mongodb-stock-plunges-after-q4-results-fy26-guidance-below-estimates">upbeat fourth-quarter results</a>.
The results came in amid a<a href="https://www.benzinga.com/earnings"> positive earnings season</a>. Here are some key analyst takeaways.
Wedbush On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00ad4e3513fb0001f03cfd/daniel-ives">Analyst Daniel Ives</a> reiterated an Outperform, while cutting the price target from $360 to $300.
MongoDB's total revenues grew 20% year-on-year to $548.4 million, beating Street expectations of $520.6 million, Ives said. Subscription revenue of $531.0 million also came in above consensus of $504.9 million, "as MDB looks to generate stable demand across industries for its next-gen solutions," he added.
NRR (net recurring revenues) stood at 118%, decelerating from 120% in the previous quarter, "due to a smaller contribution from existing customers," the analyst stated. "MongoDB provided relatively weak guidance across the board for FY26 as the company sees a more gradual impact from its AI solutions into FY26," he further wrote.
RBC Capital Markets On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846fffaee7bf6000154d142/rishi-jaluria">Analyst Rishi Jaluria</a> maintained an Outperform rating, while slashing the price target from $400 to $320.
MongoDB closed fiscal 2025 "on a solid note," with non-GAAP earnings of $1.28 per share beating consensus of 66 cents per share, Jaluria said. Although total revenues came in higher than consensus, growth decelerated by 2 points to 20% year-on-year, he added.
The company achieved strong profitability, with operating margins beating consensus by around 900 basis points, the analyst stated. Management's fiscal 2026 guidance was disappointing, being impacted by expectations of "a high single-digit decline in non-Atlas subscription revenue," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Rosenblatt Securities On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60081c88879cba00010420fb/blair-abernethy">Analyst Blair Abernethy</a> reaffirmed a Buy rating, while reducing the price target from $350 to $305.
MongoDB's subscription revenues grew by 19% year-on-year to $531 million, beating consensus by 6%, Abernethy said. The beat was driven by "greater than expected non-Atlas multi-year contract signings of ~$10m," he added.
While the company expects Atlas consumption growth to remain stable in fiscal 2026, its weaker revenue guidance for the year is impacted "largely by a $50m non-Atlas multi-year license headwind," the analyst stated. "Mongo continues to see a significant longer-term AI opportunity for its highly scalable, flexible document model that handles all data types," he further wrote.
Needham On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/601a8839a6fe6f00010c6966/mike-cikos">Analyst Mike Cikos</a> maintained a Buy rating, while slashing the price target from $415 to $270.
MongoDB guided to revenue growth of 16%-17% in the fiscal first quarter to a range of $524.0 million to $529.0 million and 12%-14% growth in fiscal 2026 to $2.240 billion to $2.280 billion, Cikos said. The full-year revenue guidance came well below Street expectations of $2.328 billion, he added.
The company expects non-Atlas subscription revenue to decline by a high-single-digit percentage, the analyst wrote. "All eyes are set squarely on Atlas (71% of Revenue) to drive revenue outperformance," with consumption growth stabilizing and the company poised to benefit from "a stronger cohort of acquired workloads in FY25 versus FY24," he further wrote.
Piper Sandler On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beeab/brent-bracelin">Analyst Brent Bracelin</a> maintained an Overweight rating, while cutting the price target from $425 to $280.
MongoDB total revenues grew 19.7% year-on-year to $548 million, "with Atlas upside contributing to a $31M beat to the midpoint guide," Bracelin said. Atlas grew by a healthy 24% year-on-year during the fiscal fourth quarter, although this marked a deceleration from the 26% reported in the previous quarter, he added.
Management indicated that Atlas consumption trends are stabilizing, the analyst stated. Bracelin said, however, that the company's growth outlook came in below 14% for second straight year.
MDB Price Action: Shares of MongoDB had declined by 21.61% to $207.06&nbsp;at the time of publication on Thursday.
Read More: &nbsp;<a href="https://www.benzinga.com/general/market-summary/25/03/44160046/marvell-surpasses-ai-chip-sales-target-aims-higher-for-2026-but-stock-plunges-due-to-muted-guidance">&nbsp;Goldman Sachs Cuts Earnings Growth Outlook, Sees Investors Move From &#8216;Excitement&#8217; To &#8216;Boredom&#8217;</a>
Photo: Shutterstock

Analyst Color

Earnings

MongoDB's Solid Q4 Overshadowed By Weak FY26 Guidance, Expects Non-Atlas Headwinds

JP Morgan analyst Reginald Smith maintains CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Neutral and lowers the price target from $16 to $15.

CMPO

JP Morgan Maintains Neutral on CompoSecure, Lowers Price Target to $15

Susquehanna analyst Joseph Stauff upgrades Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) from Negative to Neutral and maintains the price target from $30 to $30.

Upgrades

Susquehanna Upgrades Caesars Entertainment to Neutral, Maintains Price Target to $30

JP Morgan analyst Rachel Vatnsdal maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $380 to $390.

JP Morgan Maintains Neutral on Waters, Raises Price Target to $390

On Wednesday, a federal court issued a nationwide preliminary injunction against the National Institutes of Health (NIH) following its abrupt decision to slash and cap indirect cost rates on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">biomedical research grants</a>.
The ruling prevents implementing the policy change, which would affect billions of dollars in funding and disrupt ongoing <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43618745/us-states-sue-national-institutes-of-health-over-4-billion-annual-cut-in-biomedical-research-grant-budget" rel="noreferrer noopener">research and clinical trials</a>.
The controversy began when NIH released a Supplemental Guidance on February 7, 2025, modifying indirect cost rates in grant awards.
NIH said it would now&nbsp;<a target="_blank" href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-25-068.html" rel="noreferrer noopener">apply</a> a standard indirect cost rate of 15% to all new and existing grants, replacing the previous practice of negotiating separate rates for each grant.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44149348/apellis-lead-drug-pegcetacoplan-represents-differentiated-asset-jp-morgan-analyst" rel="noreferrer noopener">Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst</a>
Historically, NIH's average indirect cost rate has been around 27%–28%, with some institutions charging over 50% or even 60%.
Critics argued that the policy, issued without public notice or stakeholder input, threatened the viability of research institutions nationwide.
Three separate lawsuits were filed in response, representing 22 state attorneys general, multiple medical associations, and leading universities. Thomson Reuters published a copy of the <a href="https://fingfx.thomsonreuters.com/gfx/legaldocs/zgpojbqxnvd/03052025nih_ruling.pdf" target="_blank" rel="noreferrer noopener">lawsuit</a> online.
Plaintiffs contended that NIH's unilateral action violated federal regulations, exceeded statutory authority, and failed to comply with the Administrative Procedure Act. They also cited the potential harm to life-saving clinical trials and medical advancements.
NIH has a $48 billion budget and 27 institutes that fund critical research on diseases like&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42222191/donald-trump-nominates-pandemic-critic-jay-bhattacharya-tapped-to-reshape-national-institutes-of-health-that-oversees-budget-of-48-billion" rel="noreferrer noopener">cancer and diabetes</a>.
In 2023, NIH awarded over $35 billion in research funding across nearly 50,000 grants. Of this, $26 billion went directly to research, while $9 billion covered indirect costs.
In granting the injunction, the court determined that NIH's policy change disregarded existing laws, risked substantial harm to the nation's research infrastructure, and failed to follow proper procedures.
The decision maintains the current funding structure until the legal challenges are resolved.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44161401/rio-tintos-1-8-billion-iron-ore-expansion-ramps-up-in-australia-details" target="_blank" rel="noreferrer noopener">Rio Tinto's $1.8 Billion Iron Ore Expansion Ramps Up In Australia: Details</a></li>
</ul>
Photo via Shutterstock

Biotech

Government

Regulations

Health Care

Legal

FHLC

FTXH

HTEC

Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations

AMPY

Amplify Energy shares are trading lower after the company reported worse-than-expected Q4 financial results.

JP Morgan analyst Lisa Gill maintains Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) with a Overweight and raises the price target from $40 to $41.

OPCH

JP Morgan Maintains Overweight on Option Care Health, Raises Price Target to $41

Stifel analyst Thomas Stephan maintains Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) with a Buy and lowers the price target from $5 to $4.

Comments

Surgery Partners

Surgery Partners (SGRY) 옵션

Surgery Partners (NASDAQ:SGRY) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌